AP2656A - Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders - Google Patents

Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders

Info

Publication number
AP2656A
AP2656A AP2007004212A AP2007004212A AP2656A AP 2656 A AP2656 A AP 2656A AP 2007004212 A AP2007004212 A AP 2007004212A AP 2007004212 A AP2007004212 A AP 2007004212A AP 2656 A AP2656 A AP 2656A
Authority
AP
ARIPO
Prior art keywords
agomelatine
treatment
bipolar disorders
medicaments intended
obtaining medicaments
Prior art date
Application number
AP2007004212A
Other languages
English (en)
Other versions
AP2007004212A0 (en
Inventor
Elisabeth Mocaer
Christian De Bodinat
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2656(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AP2007004212A0 publication Critical patent/AP2007004212A0/xx
Application granted granted Critical
Publication of AP2656A publication Critical patent/AP2656A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AP2007004212A 2005-04-20 2006-04-19 Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders AP2656A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0503937A FR2884714B1 (fr) 2005-04-20 2005-04-20 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
PCT/FR2006/000859 WO2006111653A1 (fr) 2005-04-20 2006-04-19 Utilisation de l’ agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Publications (2)

Publication Number Publication Date
AP2007004212A0 AP2007004212A0 (en) 2007-10-31
AP2656A true AP2656A (en) 2013-05-07

Family

ID=35311309

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004212A AP2656A (en) 2005-04-20 2006-04-19 Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders

Country Status (40)

Country Link
US (1) US7947743B2 (de)
EP (1) EP1714647B1 (de)
JP (2) JP4580364B2 (de)
KR (2) KR100835451B1 (de)
CN (2) CN102038669A (de)
AP (1) AP2656A (de)
AR (1) AR057277A1 (de)
AT (1) ATE491443T1 (de)
AU (1) AU2006201655B2 (de)
BR (1) BRPI0601285A8 (de)
CA (1) CA2544136C (de)
CR (1) CR9426A (de)
CY (1) CY1111257T1 (de)
DE (1) DE602006018822D1 (de)
DK (1) DK1714647T3 (de)
EA (1) EA013462B1 (de)
ES (1) ES2357901T3 (de)
FR (1) FR2884714B1 (de)
GE (1) GEP20094651B (de)
GT (1) GT200600141A (de)
HR (1) HRP20110083T1 (de)
IL (1) IL186373A (de)
JO (1) JO2666B1 (de)
MA (1) MA28266A1 (de)
ME (1) ME01951B (de)
MY (1) MY143171A (de)
NO (1) NO336010B1 (de)
NZ (1) NZ546630A (de)
PE (1) PE20061337A1 (de)
PL (1) PL1714647T3 (de)
PT (1) PT1714647E (de)
RS (1) RS51659B (de)
SG (1) SG126868A1 (de)
SI (1) SI1714647T1 (de)
TN (1) TNSN07364A1 (de)
TW (2) TW200940049A (de)
UA (1) UA83681C2 (de)
UY (1) UY29470A1 (de)
WO (1) WO2006111653A1 (de)
ZA (1) ZA200603160B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
EP2150525A1 (de) 2007-05-01 2010-02-10 Concert Pharmaceuticals Inc. Naphthyl(ethyl)-acetamide
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2856934A1 (de) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarker zur Vorhersage der langfristigen Remission bei Depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5585118A (en) * 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
ATE378046T1 (de) * 2001-02-27 2007-11-15 Ortho Mcneil Pharm Inc Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality

Also Published As

Publication number Publication date
IL186373A (en) 2012-06-28
FR2884714B1 (fr) 2011-05-06
ME01951B (de) 2011-10-31
AU2006201655A1 (en) 2006-11-09
WO2006111653A1 (fr) 2006-10-26
TWI318115B (en) 2009-12-11
HK1093906A1 (en) 2007-03-16
EA200600600A1 (ru) 2006-10-27
RS51659B (sr) 2011-10-31
TW200940049A (en) 2009-10-01
JP2010280699A (ja) 2010-12-16
EP1714647B1 (de) 2010-12-15
CN1853619A (zh) 2006-11-01
HRP20110083T1 (hr) 2011-03-31
JP5341037B2 (ja) 2013-11-13
IL186373A0 (en) 2008-08-07
ZA200603160B (en) 2007-06-27
PE20061337A1 (es) 2007-01-27
UA83681C2 (uk) 2008-08-11
CA2544136C (fr) 2012-02-21
CN102038669A (zh) 2011-05-04
TW200716083A (en) 2007-05-01
US7947743B2 (en) 2011-05-24
CR9426A (es) 2008-02-21
EA013462B1 (ru) 2010-04-30
PT1714647E (pt) 2011-01-14
MA28266A1 (fr) 2006-11-01
DK1714647T3 (da) 2011-03-07
SG126868A1 (en) 2006-11-29
CN1853619B (zh) 2011-02-02
JP4580364B2 (ja) 2010-11-10
ATE491443T1 (de) 2011-01-15
CA2544136A1 (fr) 2006-10-20
PL1714647T3 (pl) 2011-05-31
US20060240127A1 (en) 2006-10-26
TNSN07364A1 (en) 2008-12-31
JP2006316056A (ja) 2006-11-24
CY1111257T1 (el) 2015-08-05
AU2006201655B2 (en) 2009-04-23
NO20061705L (no) 2006-10-23
BRPI0601285A8 (pt) 2021-03-30
ES2357901T3 (es) 2011-05-03
BRPI0601285A (pt) 2006-12-19
EP1714647A1 (de) 2006-10-25
DE602006018822D1 (de) 2011-01-27
MY143171A (en) 2011-03-31
AR057277A1 (es) 2007-11-28
NZ546630A (en) 2007-09-28
GT200600141A (es) 2006-11-22
SI1714647T1 (sl) 2011-03-31
AP2007004212A0 (en) 2007-10-31
FR2884714A1 (fr) 2006-10-27
KR20060110803A (ko) 2006-10-25
NO336010B1 (no) 2015-04-20
GEP20094651B (en) 2009-03-25
JO2666B1 (en) 2012-06-17
KR20080028389A (ko) 2008-03-31
UY29470A1 (es) 2006-05-31
KR100835451B1 (ko) 2008-06-09

Similar Documents

Publication Publication Date Title
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
GB2453188B (en) Use of compounds in the manufacture of medicaments for treatment of regional fat deposits
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
IL180078A (en) Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
AP2488A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
IL190652A0 (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
ZA200607531B (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
TWI370735B (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
PT2340872T (pt) Novas formulações farmacêuticas úteis no tratamento de insónia
IL186373A0 (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
GB2442365B (en) Methods of determining compounds useful in the treatment of bipolar disorders
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
ZA200800409B (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
IL188104A (en) Use of intravenous mixtures of valenoctamide to prepare drugs for the treatment of bipolar disorders
ZA200702866B (en) Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders
EP1956001A4 (de) Pharmazeutikum zur verwendung bei der behandlung von ureterolithiasis
IL194275A0 (en) Use of digitalis-like compounds in the treatment of affective disorders
SI2030622T1 (sl) Indikacija odmerka progesterona pri zdravljenju travmatske poškodbe možganov